Factors Associated With Posttransplant Cardiac Outcomes

Factors Associated With Short-Term Major Adverse Cardiovascular Events After Liver Transplantation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06290154

Enrollment

200

Registered

2024-03-04

Start date

2024-04-01

Completion date

2027-12-31

Last updated

2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Liver Transplantation

Brief summary

Cardiovascular disease has become the leading cause of death early after liver transplantation (LT). The aging LT population is accompanied with the increasing prevalence of cardiovascular risk factors such as hypertension, diabetes, and hyperlipidemia. Furthermore, cirrhosis has been known to cause alterations in the systemic haemodynamic system and cardiac muscle dysfunction, systolic and/or diastolic, known as Cirrhotic cardiomyopathy (CCM). Hence, transthoracic echocardiography is required in all LT candidates for preprocedural evaluation and risk stratification. However, traditional echocardiographic indices of cardiac function have low sensitivity. It is unclear whether comprehensive echocardiographic multiparameters, including speckle tracking echocardiograph (STE) and tissue doppler imaging (TDI) can help improve preoperative risk stratification. Therefore, we sought to analyze the ability of clinical and comprehensive echocardiography variables to predict intraoperative and perioperative cardiac events and cardiac mortality in our LT patient experience up to early post-liver transplant.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years, * End-stage cirrhosis patients who will receive liver transplantation, * Patients voluntarily take part in the study and write informed consent.

Exclusion criteria

* Decreased left ventricular systolic function (ejection fraction \<45%), * Significant uncorrectable structural cardiac abnormalities (eg, symptomatic coronary heart disease, advanced cardiomyopathy, severe valvular disease, severe congenital heart disease, etc), * Uncontrolled pulmonary hypertension defined as pulmonary arterial systolic pressure ≧ 35mm Hg at rest despite maximal medical management, * Circulatory or respiratory system with a score of 4 based on the preoperative Organ Dysfunction (CLIF-SOFA) score, * Second-time liver transplantation, * Combined organ transplantation, * Satisfactory quality echocardiography could not be obtained before operation.

Design outcomes

Primary

Measure	Time frame	Description
a composite outcome of new cardiovascular disease after liver transplantation	3 months after liver transplantation	new symptomatic CAD, new heart failure (systolic and/or diastolic), new arrhythmia (atrial and/or ventricular), and/or new cardiac arrest, or cardiac death.

Countries

China

Contacts

Primary ContactJia Liu, Dr

395847953@qq.com15920190962

Backup ContactJie Ren, Dr

renj@mail.sysu.edu.cn13925155583

Outcome results